UNSPSC 51191516: Hydroflumethiazide

This classification denotes a thiazide diuretic with the molecular formula C8H8F3N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 501CFL162R, chemically known as benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- but generally known as hydroflumethiazide, which bears US NIH Compound Identifier 3440. European Medicines Agency schedules Hydroflumethiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08067MIG.

UNSPSC 51191516 Hydroflumethiazide is a Commodity code that in practice covers chemical supply for municipal water treatment and pharmaceutical procurement by state and local government entities. Recent solicitations under this code show state and local governments buying sodium bisulfite for water pollution control facilities and generic multi-source pharmaceuticals through cooperative purchasing agreements. The issuing bodies include municipal water utilities (City of Meriden, Connecticut) and statewide cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement). Vendors supplying under this code must typically maintain substantial insurance coverage—General Liability of $1,000,000 to $5,000,000 depending on the scope, commercial auto coverage, and compliance certifications such as cGMP and the Drug Supply Chain Security Act for pharmaceutical products. Pricing evaluation weighs fixed or competitive pricing heavily, with administrative fees of 3 percent common in cooperative purchasing vehicles.

The City of Meriden issued RFQ B02715 on July 8, 2026, for sodium bisulfite delivery to its Water Pollution Control Facility, with bids due July 29, 2026; pricing is evaluated on a unit-cost basis with firm bids required for the contract period. MMCAP issued a multi-source pharmaceutical RFP (S1070000015802) posted January 20, 2026, with proposals due March 26, 2026, to establish contracts effective July 1, 2026, across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions; evaluation weighted price competitiveness at 75 percent, fixed pricing at 10 percent, and administrative compliance (EDI capability, data format, fee structure agreement) at 15 percent combined. Recent activity centers in the Northeast and Upper Midwest, with MMCAP's cooperative model distributing products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC as authorized wholesalers.